UBS Group’s Nasus Pharma NSRX Stock Holding History

UBS Group’s Portfolio NSRX Stock Details NSRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.87K	Buy	3,094 +2,716	+719%	+$14K	﹤0.01%	8644
2025 Q4	$3.46K	Sell	378 -863	-70%	-$6.34K	﹤0.01%	9018
2025 Q3	$8.25K	Buy	+1,241	New	+$9.99K	﹤0.01%	8672

Other funds holding NSRX

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's NSRX Position: Q1 2026 in Review

UBS Group increased its Nasus Pharma (NSRX) stake by 719% in Q1 2026, buying an estimated $14K and bringing the position to 3,094 shares worth $6.87K. The position accounts for ﹤0.01% of the portfolio, ranked #8644.

UBS Group first reported a position in NSRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $8.25K in Q3 2025. 9 funds tracked by Wall St. Rank hold NSRX as of Q1 2026.

UBS Group held 3,094 shares of Nasus Pharma worth $6.87K as of Q1 2026.
UBS Group bought 2,716 Nasus Pharma shares in Q1 2026, an estimated $14K.
Nasus Pharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8644 holding.
UBS Group first reported a position in Nasus Pharma in Q3 2025 and has held it in 3 quarters since.
UBS Group's Nasus Pharma position peaked at $8.25K in Q3 2025.
9 funds tracked by Wall St. Rank held Nasus Pharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.